VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release first quarter financial results for the period ended March 31, 2022 on Tuesday, May 17 before market open. Professor Dror Harats, M.D, Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update.
About VBL Therapeutics
IoT Evolution Expo #TECHSUPERSHOW Expo Hall Open
Simplify Cybersecurity with Managed Security Operations
Conference Luncheon - For Paid Conference Pass Holders, Exhibitors, Sponsors, Speakers, Press